Outlook Therapeutics Inc (OTLK)

$7.96

-0.15

(-1.85%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $7.90
    $8.12
    $7.96
    downward going graph

    0.75%

    Downside

    Day's Volatility :2.73%

    Upside

    1.99%

    downward going graph
  • $4.00
    $35.00
    $7.96
    downward going graph

    49.75%

    Downside

    52 Weeks Volatility :88.57%

    Upside

    77.26%

    downward going graph

Returns

PeriodOutlook Therapeutics IncIndex (Russel 2000)
3 Months
-1.61%
0.0%
6 Months
17.06%
0.0%
1 Year
-76.31%
0.0%
3 Years
-83.95%
-19.6%

Highlights

Market Capitalization
189.8M
Book Value
- $6.1
Earnings Per Share (EPS)
-11.91
Wall Street Target Price
37.49
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-66.19%
Return On Equity TTM
-3.65%
Revenue TTM
5.9M
Revenue Per Share TTM
0.12
Quarterly Revenue Growth YOY
658.3000000000001%
Gross Profit TTM
-42.3M
EBITDA
-59.8M
Diluted Eps TTM
-11.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-9.48
EPS Estimate Next Year
-2.52
EPS Estimate Current Quarter
-0.85
EPS Estimate Next Quarter
-0.9

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Outlook Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 370.98%

Current $7.96
Target $37.49

Technicals Summary

Sell

Neutral

Buy

Outlook Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Outlook Therapeutics Inc
Outlook Therapeutics Inc
7.13%
17.06%
-76.31%
-83.95%
-83.82%
Moderna, Inc.
Moderna, Inc.
-11.58%
21.5%
-1.52%
-62.55%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.03%
12.81%
46.27%
81.23%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.55%
24.69%
62.32%
198.21%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.5%
11.69%
37.68%
150.78%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Outlook Therapeutics Inc
Outlook Therapeutics Inc
NA
NA
NA
-9.48
-0.04
-0.66
NA
-6.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Outlook Therapeutics Inc
Outlook Therapeutics Inc
Buy
$189.8M
-83.82%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Outlook Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 135.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 198.2% return, outperforming this stock by 282.2%

Institutional Holdings

  • TANG CAPITAL MANAGEMENT LLC

    6.92%
  • Great Point Partners LLC

    6.32%
  • Armistice Capital, LLC

    3.05%
  • Sphera Funds Management Ltd.

    2.44%
  • BlackRock Inc

    2.15%
  • Velan Capital Investment Management LP

    2.14%

Company Information

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t

Organization
Outlook Therapeutics Inc
Employees
24
CEO
Mr. Ralph H. Thurman
Industry
Health Technology

FAQs